Advertisement

Journal of Gastroenterology

, Volume 46, Issue 4, pp 492–500 | Cite as

Diagnosis of ischemic small bowel disease by measurement of serum intestinal fatty acid-binding protein in patients with acute abdomen: a multicenter, observer-blinded validation study

  • Tatsuo KandaEmail author
  • Akihiro Tsukahara
  • Kyo Ueki
  • Yasuo Sakai
  • Tatsuo Tani
  • Atsushi Nishimura
  • Toshiyuki Yamazaki
  • Yoichi Tamiya
  • Tetsuya Tada
  • Masaki Hirota
  • Jun Hasegawa
  • Hiroyuki Funaoka
  • Hiroshi Fujii
  • Katsuyoshi Hatakeyama
Original Article—Alimentary Tract

Abstract

Background

Intestinal fatty acid-binding protein (I-FABP) is a low-molecular-mass (15 kDa) cytosolic protein found exclusively in the epithelial cells of the small bowel mucosa. We aimed to evaluate the clinical usefulness of serum I-FABP measurement for the diagnosis of ischemic small bowel disease.

Methods

Patients with a clinical diagnosis of acute abdomen were recruited for this multicenter trial at one university hospital and nine city hospitals over a 13-month period. Serum I-FABP levels were measured in 361 eligible patients by an enzyme-linked immunosorbent assay using a specific monoclonal antibody.

Results

Of the 361 patients, 242 underwent surgery, and small bowel ischemia was diagnosed in 52 patients. The mean serum I-FABP level in the patients with small bowel ischemia was 40.7 ± 117.9 ng/ml, which was significantly higher than that in patients with non-ischemic small bowel disease (5.8 ± 15.6 ng/ml) and those with non-small bowel disease (1.8 ± 1.7 ng/ml). The serum I-FABP cutoff level for the diagnosis of small bowel ischemia was 3.1 ng/ml. Serum I-FABP was more efficient than conventional biochemical markers, in terms of sensitivity and positive and negative predictive values, in the diagnosis of small bowel ischemia. However, its specificity was slightly lower than that of creatinine phosphokinase or lactate dehydrogenase. The positive and negative likelihood ratios of serum I-FABP were 3.01 and 0.29, respectively.

Conclusion

Serum I-FABP measurement is a non-invasive method that is potentially useful for the efficient identification of patients with acute abdomen who are at risk of small bowel ischemia.

Keywords

Acute abdomen Biomarker ELISA I-FABP Intestinal ischemia 

Notes

Acknowledgments

We wish to thank Dr. K. Akazawa, Professor of the Division of Information Science and Biostatistics, Niigata University Graduate School of Medical and Dental Sciences, for helpful advice on statistical analysis.

References

  1. 1.
    Martin B. Prevention of gastrointestinal complications in the critically ill patients. AACN Adv Crit Care. 2007;18:158–66.PubMedCrossRefGoogle Scholar
  2. 2.
    Angelelli G, Scardapane A, Memeo M, Stabile Ianora AA, Rotondo A. Acute bowel ischemia: CT findings. Eur J Radiol. 2004;50:37–47.PubMedCrossRefGoogle Scholar
  3. 3.
    Kozuch PL, Brandt LJ. Review article: diagnosis and management of mesenteric ischemia with an emphasis on pharmacotherapy. Aliment Pharmacol Ther. 2005;21:201–15.PubMedCrossRefGoogle Scholar
  4. 4.
    Evennett NJ, Petrov MS, Mittal A, Windsor JA. Systematic review and pooled estimates for the diagnostic accuracy of serological markers for intestinal ischemia. World J Surg. 2009;33:1374–83.PubMedCrossRefGoogle Scholar
  5. 5.
    Alpers DH, Strauss AW, Ockner RK, Bass NM, Gordon JI. Cloning of a cDNA encoding rat intestinal fatty acid-binding protein. Proc Natl Acad Sci USA. 1984;81:313–7.PubMedCrossRefGoogle Scholar
  6. 6.
    Agellon LB, Toth MJ, Thomson AB. Intracellular lipid binding proteins of the small intestine. Mol Cell Biochem. 2002;239:79–82.PubMedCrossRefGoogle Scholar
  7. 7.
    Pelsers MM, Namiot Z, Kisielewski W, Namiot A, Januszkiewicz M, Hermens WT, et al. Intestinal-type and liver-type fatty acid-binding protein in the intestine. Tissue distribution and clinical utility. Clin Biochem. 2003;36:529–35.PubMedCrossRefGoogle Scholar
  8. 8.
    Kanda T, Nakatomi Y, Ishikawa H, Hitomi M, Matsubara Y, Ono T, et al. Intestinal fatty acid-binding protein as a sensitive marker of intestinal ischemia. Dig Dis Sci. 1992;37:1362–7.PubMedCrossRefGoogle Scholar
  9. 9.
    Kanda T, Fujii H, Fujita M, Sakai Y, Ono T, Hatakeyama K. Intestinal fatty acid-binding protein is available for diagnosis of intestinal ischaemia: immunochemical analysis of two patients with ischaemic intestinal diseases. Gut. 1995;36:788–91.PubMedCrossRefGoogle Scholar
  10. 10.
    Kanda T, Fujii H, Tani T, Murakami H, Suda T, Sakai Y, et al. Intestinal fatty acid-binding protein is a useful diagnostic marker for mesenteric infarction in humans. Gastroenterology. 1996;110:339–43.PubMedCrossRefGoogle Scholar
  11. 11.
    Marks WH, Gollin G. Biochemical detection of small intestinal allograft rejection by elevated circulating levels of serum intestinal fatty acid-binding protein. Surgery. 1993;114:206–10.PubMedGoogle Scholar
  12. 12.
    Morrisseve PE, Gollin G, Marks WH. Small bowel allograft rejection detected by serum intestinal fatty acid-binding protein is reversible. Transplantation. 1996;61:1451–5.CrossRefGoogle Scholar
  13. 13.
    Gollin G, Marks WH. Elevation of circulating intestinal fatty acid-binding protein in a luminal contents-initiated model of NEC. J Pediatr Surg. 1993;28:367–70.PubMedCrossRefGoogle Scholar
  14. 14.
    Guthmann F, Börchers T, Wolfrum C, Wustrack T, Bartholomäus S, Spener F. Plasma concentration of intestinal- and liver-FABP in neonates suffering from necrotizing enterocolitis and in healthy preterm neonates. Mol Cell Biochem. 2002;239:227–34.PubMedCrossRefGoogle Scholar
  15. 15.
    Wiercinska-Drapalo A, Jaroszewicz J, Siwak E, Pogorzelska J, Prokopowicz D. Intestinal fatty acid-binding protein (I-FABP) as a possible biomarker of ileitis in patients with ulcerative colitis. Regul Pept. 2008;147:25–8.PubMedCrossRefGoogle Scholar
  16. 16.
    Kajiura S, Yashiki T, Funaoka H, Ohkaru Y, Nishikura K, Kanda T, et al. Establishment and characterization of monoclonal and polyclonal antibodies against human intestinal fatty acid-binding protein (I-FABP) using synthetic regional peptides and recombinant I-FABP. J Immunoassay Immunochem. 2008;29:19–41.PubMedCrossRefGoogle Scholar
  17. 17.
    Funaoka H, Kanda T, Kajiura S, Ohkaru Y, Fujii H. Development of a high-specificity sandwich ELISA system for the quantification of human intestinal fatty acid-binding protein (I-FABP) concentrations. Immunol Invest. 2011;40:1–20.CrossRefGoogle Scholar
  18. 18.
    Newcombe RG. Improved confidence intervals for the difference between binomial proportions based on paired data. Stat Med. 1998;17:2635–50.PubMedCrossRefGoogle Scholar
  19. 19.
    Simel DL, Samsa GP, Matchar DB. Likelihood ratios with confidence: sample size estimation for diagnostic test studies. J Clin Epidemiol. 1991;44:763–70.PubMedCrossRefGoogle Scholar
  20. 20.
    Hanssen SJ, Derikx JP, Vermeulen Windsant IC, Heijmans JH, Koeppel TA, Schurink GW, et al. Visceral injury and systemic inflammation in patients undergoing extracorporeal circulation during aortic surgery. Ann Surg. 2008;248:117–25.PubMedCrossRefGoogle Scholar
  21. 21.
    Kim JH, Ha HK, Kim JK, Eun HW, Park KB, Kim BS, et al. Usefulness of known computed tomography and clinical criteria for diagnosing strangulation in small-bowel obstructions: analysis of true and false interpretation groups in computed tomography. World J Surg. 2004;28:63–8.PubMedCrossRefGoogle Scholar
  22. 22.
    Weisner W, Hauser A, Steinbrich W. Accuracy of multidetector row computed tomography for the diagnosis of acute bowel ischemia in a non-selected study population. Eur Radiol. 2004;14:2347–56.CrossRefGoogle Scholar
  23. 23.
    Berrigton de Gonzalez A, Mahesh M, Bhagavan M, Lewis R, Mettler F, Land C. Projected cancer risks from computed tomographic scans performed in the United States in 2007. Arch Intern Med. 2009;169:2071–7.CrossRefGoogle Scholar
  24. 24.
    The 2007 recommendations of the International Commission on Radiological Protection: ICRP publication 103. Ann ICRP. 2007;37:1–332.Google Scholar
  25. 25.
    Board on Radiation Effects Research (BRER). Health risks from exposure to low levels of ionizing radiation: BEIR VII phase 2. Washington, DC: National Academies Press; 2006.Google Scholar

Copyright information

© Springer 2011

Authors and Affiliations

  • Tatsuo Kanda
    • 1
    Email author
  • Akihiro Tsukahara
    • 2
  • Kyo Ueki
    • 3
  • Yasuo Sakai
    • 4
  • Tatsuo Tani
    • 1
  • Atsushi Nishimura
    • 5
  • Toshiyuki Yamazaki
    • 6
  • Yoichi Tamiya
    • 7
  • Tetsuya Tada
    • 8
  • Masaki Hirota
    • 9
  • Jun Hasegawa
    • 10
  • Hiroyuki Funaoka
    • 11
  • Hiroshi Fujii
    • 12
  • Katsuyoshi Hatakeyama
    • 1
  1. 1.Division of Digestive and General SurgeryNiigata University Graduate School of Medical and Dental SciencesNiigataJapan
  2. 2.Department of SurgeryNiigata Prefecture Shibata HospitalShibataJapan
  3. 3.Department of SurgeryKariwagun General HospitalKashiwazakiJapan
  4. 4.Department of SurgerySaiseikai Niigata Daini HospitalNiigataJapan
  5. 5.Department of SurgeryNagaoka Chuo General HospitalNagaokaJapan
  6. 6.Department of SurgeryNiigata City General HospitalNiigataJapan
  7. 7.Department of SurgeryNiigata Prefecture Yoshida HospitalTsubameJapan
  8. 8.Department of SurgeryTachikawa General HospitalNagaokaJapan
  9. 9.Department of SurgeryNiigata Prefecture Muikamachi HospitalMinamiuonumaJapan
  10. 10.Department of SurgeryJapanese Red Cross Nagaoka HospitalNagaokaJapan
  11. 11.DS Pharma Biomedical Co., Ltd.OsakaJapan
  12. 12.Department of Bioscience and BiotechnologyShinshu UniversityNaganoJapan

Personalised recommendations